# US 2023/0265123 A1 · Peptides and formulations for cancer treatment

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0265123 A1
- Document ID: US20230265123A1
- Status: Published application
- Kind: A1
- Application number: 18/041,289
- Filed: 2021-08-10
- Published: 2023-08-24
- Earliest claimed: 2020-08-11
- Assignees: Peptinovo Biopharma, LLC
- Applicants: Peptinovo Biopharma, Inc.
- Inventors: Reynold Homan
- Web page: https://patentgrep.com/patent/US20230265123A1

## CPC

- C07K 7/08: having 12 to 20 amino acids (gastrins C07K14/595; somatostatins C07K14/655; melanotropins C07K14/68)
- A61K 9/5123: {Organic compounds, e.g. fats, sugars}
- A61K 31/337: having four-membered rings, e.g. taxol
- A61K 31/4375: the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
- A61K 31/4745: condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines (yohimbine derivatives, vinblastine A61K31/475; ergoline derivatives A61K31/48)
- A61K 31/704: attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin {(digitoxin A61K31/7048)}
- A61K 31/7068: having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K 31/7076: containing purines, e.g. adenosine, adenylic acid
- A61K 38/05: Dipeptides
- A61K 38/07: Tetrapeptides
- A61K 47/186: {Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide}
- A61K 47/542: {Carboxylic acids, e.g. a fatty acid or an amino acid}
- A61K 47/554: {the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid}
- A61K 47/6907: {the form being a microemulsion, nanoemulsion or micelle}
- A61K 51/0408: {Phospholipids (liposomes encapsulating the radioactive probe or having no radiolabelled phospholipids A61K51/1231)}
- A61K 51/08: Peptides, e.g. proteins {, carriers being peptides, polyamino acids, proteins}
- A61P 35/00: Antineoplastic agents
- C07K 14/001: {by chemical synthesis}
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Novel amphiphilic peptide, peptide amphiphile lipid micelles, processes for making peptide amphiphile lipid micelles comprising an amphiphilic peptide and phospholipid and optionally comprising a cargo molecule, and methods of use.

## Claims

### Claim 1

A peptide comprising an amino acid sequence: X1-X2-X3-X4-X5-X6-X7-X8-X9-X10-X11-X12-X13-X14-X15-X16-X17-X18-X19-X20, wherein: X1 is D; X2 is V, Aib, Amy, or Aml; X3 and X10 are each F; X4 and X19 are each Q; X5, X16, and X18 are each K; X6, X9, and X13 are each L; X7 and X14 are each independently selected from the group consisting of Aib, Amy, Aml, Amp, Amt; X8 and X15 are each E; X11 and X12 are each independently selected from the group consisting of Q and N; X17 is W; and X20 is V, (SEQ ID NO:12) wherein the peptide is optionally acylated at the N-terminus, amidated at the C-terminus, or both acylated at the N-terminus and amidated at the C-terminus and the peptide is from 20 to 24 amino acids in length.

### Claim 2 (depends on 1)

The peptide of claim 1, wherein the peptide is 20 amino acids in length.

### Claim 3

A peptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:7, SEQ ID NO:9, or SEQ ID NO:10, wherein the peptide is optionally acylated at the N-terminus, amidated at the C-terminus, or both acylated at the N-terminus and amidated at the C-terminus and the peptide is from 20 to 24 amino acid in length.

### Claim 4 (depends on 3)

The peptide according to claim 3, wherein the amino acid consists essentially of the amino acid sequence SEQ ID NO:7, SEQ ID NO:9, or SEQ ID NO:10, wherein the peptide is optionally acylated at the N-terminus, amidated at the C-terminus, or both acylated at the N-terminus and amidated at the C-terminus and the peptide is from 20 to 24 amino acid in length.

### Claim 5 (depends on 3)

The peptide according to claim 3, consisting of the amino acid sequence SEQ ID NO:7, SEQ ID NO:9, or SEQ ID NO:10, wherein the peptide is optionally acylated at the N-terminus, amidated at the C-terminus, or both acylated at the N-terminus and amidated at the C-terminus and the peptide is 20 amino acid in length.

### Claim 6 (depends on 3)

The peptide according to claim 3, consisting of the amino acid sequence SEQ ID NO:7, SEQ ID NO:9, or SEQ ID NO:10, wherein the peptide is not acylated or amidated.

### Claim 7 (depends on 6)

The peptide according to claim 6, wherein the amino acid sequence is SEQ ID NO:7.

### Claim 8 (depends on 1)

A peptide-amphiphile lipid micelle (PALM) comprising a peptide according to claim 1, and a lipid component comprising sphingomyelin and one or more additional phospholipids.

### Claim 9 (depends on 8)

The PALM according to claim 8, wherein the one or more additional phospholipid is selected from the group consisting of phosphatidylcholine, polyethylene glycol-phosphatidylethanolamine (PEG-PE), phosphatidylethanolamine, phosphatidylglycerol, phosphatidylserine, phosphatidylinositol, cardiolipin, or any combination thereof.

### Claim 10 (depends on 8)

The PALM according to claim 8, wherein the one or more additional phospholipid comprises a phosphatidylcholine.

### Claim 11 (depends on 10)

The PALM according to claim 10, wherein the phosphatidylcholine is 1-palmitoyl-2-oleoyl-phosphatidylcholine (POPC).

### Claim 12 (depends on 8)

The PALM according to claim 8, wherein the molar ratio of phospholipid to sphingomyelin is from about 80:20 to about 60:40.

### Claim 13 (depends on 12)

The PALM according to claim 12, wherein the molar ratio of phospholipid to sphingomyelin is about 70:30.

### Claim 14 (depends on 8)

The PALM according to claim 8, wherein the molar ratio of the lipid component to peptide is from about 10:1 to about 2:1.

### Claim 15 (depends on 13)

The PALM according to claim 13, wherein the molar ratio of the lipid component to peptide is from about 6:1 to about 4:1.

### Claim 16 (depends on 8)

The PALM according to claim 8, wherein the PALM has a mean particle diameter is from about 7.5 nm to about 20 nm.

### Claim 17 (depends on 8)

A PALM-cargo composition comprising the PALM according to claim 8, and at least one cargo molecule.

### Claim 18 (depends on 17)

The PALM-cargo composition according to claim 17, wherein the at least one cargo molecule is a compound conjugate having the formula (I):
A-R-L-X (formula I)
wherein A is an agent having a hydroxyl or an amine group; R is the hydroxyl group or the amine group of the agent; L is a linker; and X is an anchor moiety.

### Claim 19 (depends on 18)

The PALM-cargo composition of claim 18, wherein the anchor moiety X is cholesterol, α-tocotrienol, β-tocotrienol, γ-tocotrienol, and δ-tocotrienol, cholecalciferol, or ergocalciferol.

### Claim 20 (depends on 19)

The PALM-cargo composition of claim 19, wherein L is diglycolic acid, carbonic acid, or succinic acid.

### Claim 21 (depends on 19)

The PALM-cargo composition of claim 19, wherein R is the hydroxyl group and the anchor moiety is covalently bonded to the agent by a carbonate ester bond, or a succinic ester bond, or a diglycolic ester bond.

### Claim 22 (depends on 19)

The PALM-cargo composition of claim 19, wherein R is an amine group and the anchor moiety is covalently bonded to the agent by a carbamate ester bond, or a succinic ester bond, or a diglycolic ester bond.

### Claim 23 (depends on 18)

The PALM-cargo composition according to claim 18, wherein the agent is a chemotherapeutic agent.

### Claim 24 (depends on 23)

The PALM-cargo composition according to claim 23, wherein the chemotherapeutic agent is selected from the group consisting of adenosine, AZD2811, bortezomib, 10-hydroxy camptothecin, 7-ethyl-10-hydroxycamptothecin, daunorubicin, docetaxel, doxorubicin, eribulin, gemcitabine, ixabepilone, mertansine, miriplatin, misonidazole, paclitaxel, topotecan, tubulysin A, vincristine, vinblastine, vinorelbine, and combinations thereof.

### Claim 25 (depends on 24)

The PALM-cargo composition according to claim 24, wherein the chemotherapeutic agent is 10-hydroxy camptothecin, daunorubicin, doxorubicin, gemcitabine, topotecan, paclitaxel, or docetaxel.

### Claim 26 (depends on 24)

The PALM-cargo composition according to claim 24, wherein the compound conjugate is paclitaxel 2′-□-tocotrienyl carbonate; paclitaxel 2′-cholesteryl carbonate; docetaxel 2′-cholesteryl carbonate; daunorubicin □-tocotrienyl carbonate; gemcitabine cholesteryl carbonate; 10-hydroxycampothecin cholesterol carbonate, or 7-ethyl-10-hydroxycamptothecin cholesteryl carbonate.

### Claim 27 (depends on 18)

The PALM-cargo composition according to claim 18, wherein the PALM-cargo composition further comprises an imaging agent.

### Claim 28 (depends on 27)

The PALM-cargo composition according to claim 27, wherein the imaging agent is 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine-N-diethylenetriaminepentaacetic acid (gadolinium salt) (PE-DTPA(Gd)), 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine-N-diethylenetriaminepentaacetic acid (manganese salt) (PE-DTPA(Mn)), 111In-DTPA-A (indium salt).

### Claim 29 (depends on 18)

The PALM-cargo composition according to claim 18, wherein the peptide is SEQ ID NO:7, SEQ ID NO:9, or SEQ ID NO:10.

### Claim 30 (depends on 18)

The PALM-cargo composition according to claim 18, wherein the peptide is SEQ ID NO:7.

### Claim 31 (depends on 18)

A method for treating a disorder comprising administering to a subject in need thereof, an effective amount of a PALM-cargo composition according to claim 18.

### Claim 32 (depends on 31)

The method for treating a disorder according to claim 31, wherein the peptide in the PALM-cargo composition is SEQ ID NO:7, SEQ ID NO:9, or SEQ ID NO:10.

### Claim 33 (depends on 32)

The method for treating a disorder according to claim 32, wherein the peptide in the PALM-cargo composition is SEQ ID NO:7.

### Claim 34 (depends on 32)

The method for treating a disorder according to claim 32, wherein the drug is a chemotherapeutic agent.

### Claim 35 (depends on 34)

The method for treating a disorder according to claim 34, wherein the chemotherapeutic agent in the PALM-cargo composition is 10-hydroxy camptothecin, daunorubicin, doxorubicin, gemcitabine, topotecan, paclitaxel, or docetaxel.

### Claim 36 (depends on 31)

The method according to claim 31, wherein the disorder is cancer.

### Claim 37 (depends on 36)

The method according to claim 36, wherein the cancer is ovarian cancer, cervical cancer, colorectal cancer, prostate cancer, breast cancer, gastric adenocarcinoma, head and neck cancer, testicular cancer, leukemia, neuroblastoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, and non-small cell lung cancer.
